Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
April 5, 2019 Off

Global Anterior Uveitis Clinical Trials Review, H2, 2018 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Anterior Uveitis Global Clinical Trials Review, H2, 2018” clinical trials has been added to ResearchAndMarkets.com’s offering. Anterior Uveitis…

April 5, 2019 Off

Global Parkinson’s Disease Drugs Market is Expected to Witness a CAGR of 7.2% to Reach Revenue of $5,614.6 Million by 2024 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Global Parkinson’s Disease Drugs Market 2018-2024” report has been added to ResearchAndMarkets.com’s offering. Global Parkinson’s Disease Drugs Market…

April 5, 2019 Off

Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA

By BusinessWire

BLA submission includes both myelodysplastic syndromes and beta-thalassemia indications EMA marketing application for both indications planned for Q2:19 SUMMIT, N.J.…

Onvansertib in Trovagene trial safe and well tolerated in difficult-to-treat relapsed or refractory AML patients
April 5, 2019 Off

Onvansertib in Trovagene trial safe and well tolerated in difficult-to-treat relapsed or refractory AML patients

By Dino Mustafić

Trovagene said that additional data from its ongoing Phase 1b/2 study of onvansertib combined with standard-of-care chemotherapy in Acute Myeloid…

Indivor study finds 75% patients abstinent from illicit opioids a full year after receiving 12 monthly doses of Suboclade
April 5, 2019 Off

Indivor study finds 75% patients abstinent from illicit opioids a full year after receiving 12 monthly doses of Suboclade

By Dino Mustafić

Indivior’s “Recover” study found that 75% of patients who had received 12 once-monthly doses of sublocade in a Phase 3 clinical trial were abstinent from illicit opioids for a year after the study ended. In this observational study, abstinence was defined as self-report confirmed by urine drug screen.

April 5, 2019 Off

Juvenile Macular Degeneration (Stargardt Disease) Pipeline Review, H1 2019 Report – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.…

AgeX Therapeutics to Present at Master Investor Show 2019
April 5, 2019 Off

AgeX Therapeutics to Present at Master Investor Show 2019

By BusinessWire

ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced today…

April 5, 2019 Off

Crigler-Najjar Syndrome – Pipeline Review, H1 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Crigler-Najjar Syndrome – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Crigler-Najjar Syndrome –…

Syros Announces Pricing of $70 Million Concurrent Public Offerings
April 5, 2019 Off

Syros Announces Pricing of $70 Million Concurrent Public Offerings

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today…

Jnana Therapeutics Appoints Donald Nicholson, Ph.D., as Chair of its Board of Directors
April 5, 2019 Off

Jnana Therapeutics Appoints Donald Nicholson, Ph.D., as Chair of its Board of Directors

By BusinessWire

BOSTON–(BUSINESS WIRE)–Jnana Therapeutics today announced the appointment of Donald Nicholson, Ph.D., an accomplished scientist and executive, as chair of its…

Posts pagination

Previous 1 … 3,298 3,299 3,300 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine